# A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer

> **NCT00333775** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 736 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Placebo to bevacizumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00333775
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2007-10
- **Final completion:** 2013-10
- **Target enrollment:** 736 (ACTUAL)
- **Last updated:** 2016-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00333775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00333775, "A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00333775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*